POLE and colorectal carcinoma: For patients with hyper-mutated subtypes of CRC—specifically those with microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) CRC or those with hereditary mutations in the exonuclease domain of the polymerase epsilon, catalytic subunit (POLE)—ICIs have shown remarkable efficacy with a more favorable toxicity profile than traditional chemotherapy [6].